ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,025.99
-0.95%
Dow Jones
44,303.40
-0.99%
US Dollar vs MXN
20.5715
0.00%
Brent Oil
74.565
0.00%
Bitcoin
96,520.05
-0.03%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Enanta Pharmaceuticals Inc (ENTA) Cotización

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc (ENTA)

NASDAQ
4.90
-0.06
(-1.21%)
Cerrado 07 Febrero 3:00PM
Delayed by 15 minutes
4.90
0.00
(0.00%)
Fuera de horario: 4:56PM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
4.90
Postura de Compra
4.82
Postura de Venta
5.31
Volume Operado de la Acción
425,426
4.81 Rango del Día 5.02
4.71 Rango de 52 semanas 17.80
Capitalización de Mercado [m]
103.852M
Precio Anterior
4.96
Precio de Apertura
5.01
Hora
130
@
4.9
(priorref)
Última hora de negociación
Volumen financiero
US$ 2,081,853
Precio Promedio Ponderado
4.8936
Volumen promedio (3 m)
546,160
Acciones en circulación
21,194,326
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.89
Beneficio por acción (BPA)
-5.48
turnover
67.64M
Beneficio neto
-116.05M

Acerca de Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of... Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.enanta.com
Sede
Wilmington, Delaware, USA
Fundado
-
Enanta Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENTA. The last closing price for Enanta Pharmaceuticals was US$4.96. Over the last year, Enanta Pharmaceuticals shares have traded in a share price range of US$ 4.71 to US$ 17.80.

Enanta Pharmaceuticals currently has 21,194,326 shares in issue. The market capitalisation of Enanta Pharmaceuticals is US$105.12 million. Enanta Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.89.

ENTA Últimas noticias

Más noticias

Form ARS - Annual Report to Security Holders

27 Enero 2025
Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

27 Enero 2025
Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements

27 Enero 2025
Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

22 Enero 2025
Edgar (US Regulatory)

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R...

08 Enero 2025
Business Wire

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the...

24 Diciembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

10 Diciembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Diciembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Diciembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Diciembre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.1723-3.39688109935.07235.30674.883154365.0796284CS
4-0.11-2.195608782445.015.75974.714640055.06421301CS
12-5.34-52.148437510.2410.454.715461606.40869199CS
26-8.33-62.96296296313.2313.54.713251917.80829654CS
52-7.63-60.893854748612.5317.84.7126328010.17159481CS
156-56.09-91.965896048560.9979.4954.7125456225.8851597CS
260-50.2-91.107078039955.11024.7121979334.64363849CS

ENTA - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Enanta Pharmaceuticals?
El precio actual de las acciones de Enanta Pharmaceuticals es US$ 4.90
¿Cuántas acciones de Enanta Pharmaceuticals están en circulación?
Enanta Pharmaceuticals tiene 21,194,326 acciones en circulación
¿Cuál es la capitalización de mercado de Enanta Pharmaceuticals?
La capitalización de mercado de Enanta Pharmaceuticals es USD 105.12M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Enanta Pharmaceuticals?
Enanta Pharmaceuticals ha negociado en un rango de US$ 4.71 a US$ 17.80 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Enanta Pharmaceuticals?
El ratio precio/beneficio de Enanta Pharmaceuticals es -0.89
¿Cuál es el ratio de efectivo a ventas de Enanta Pharmaceuticals?
El ratio de efectivo a ventas de Enanta Pharmaceuticals es 1.54
¿Cuál es la moneda de reporte de Enanta Pharmaceuticals?
Enanta Pharmaceuticals presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Enanta Pharmaceuticals?
El último ingresos anual de Enanta Pharmaceuticals es USD 67.64M
¿Cuál es el último beneficio anual de Enanta Pharmaceuticals?
El último beneficio anual de Enanta Pharmaceuticals es USD -116.05M
¿Cuál es la dirección registrada de Enanta Pharmaceuticals?
La dirección registrada de Enanta Pharmaceuticals es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de Enanta Pharmaceuticals?
La dirección del sitio web de Enanta Pharmaceuticals es www.enanta.com
¿En qué sector industrial opera Enanta Pharmaceuticals?
Enanta Pharmaceuticals opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
780.33M
CDTConduit Pharmaceuticals Inc
US$ 2.831
(82.65%)
140.32M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
215.16M
TOIIWOncology Institute Inc
US$ 0.033
(58.88%)
7.27k
CYTHCyclo Therapeutics Inc
US$ 1.19
(54.55%)
72.39M
FTELFitell Corporation
US$ 2.70
(-57.01%)
2.28M
SGBXSafe and Green Holdings Corporation
US$ 0.6401
(-44.82%)
5.15M
NKLANikola Corporation
US$ 0.4432
(-41.10%)
47.43M
PLRXPliant Therapeutics Inc
US$ 7.785
(-34.85%)
6.4M
LIPOLipella Pharmaceuticals Inc
US$ 3.08
(-33.76%)
2.08M
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
780.33M
RIMEAlgorhythm Holdings Inc
US$ 0.0169
(-20.66%)
262.79M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
215.16M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0537
(14.74%)
210.77M
NVDANVIDIA Corporation
US$ 129.84
(0.90%)
209.03M

ENTA Discussion

Ver más
alertmeipp alertmeipp 43 minutos hace
Actually nothing that unusual especially when the public failed miserably to value the company properly.

But not sure how that would translate to later than usual quarter release
👍️0
rwwine rwwine 2 horas hace
"One possibility is that ENTA has hired an investment bank to evaluate “strategic alternatives” that enhance shareholder value—an action that would presumably be well received by the market."


Respectfully have a different opinion.  If this is the case (hiring an investment bank), I personally view that approach as a negative for ENTA.  That approach suggests the corporate executives have lost their way, specifically implying a lack of confidence in their approach going forward.  Just my simplistic point of view sir.  No disrespect.

👍️0
alertmeipp alertmeipp 4 horas hace
But how would strategic alternatives evaluation delay the quarter release, I mean unless something is bound to happen rather soon - like in next few days? Otherwise, they just need to add a mention to the release and should be good to go?
👍 2
DewDiligence DewDiligence 5 horas hace
One possibility is that ENTA has hired an investment bank to evaluate “strategic alternatives” that enhance shareholder value—an action that would presumably be well received by the market.

In any event, I’m not unduly concerned about the company’s radio silence. ENTA has plenty of inherent value that will be realized by shareholders one way or another.
👍️ 3
dewophile dewophile 5 horas hace
Yes it is odd eom
👍️0
dewophile dewophile 5 horas hace
Yes totally agree
👍️ 1
go seek go seek 6 horas hace
If ENTA planned to release earnings Monday, wouldn’t we have an announcement of that today? To me the lack of transparency around earnings date is odd.
👍️0
alertmeipp alertmeipp 6 horas hace
I agree that it’s negative in the sense that it introduced additional uncertainties on the balance sheet, especially when viewed alongside the strong 323 data. However, this is now a moot point since they plan to partner out the asset.

Overall, I don’t see the data as inherently negative. Given the trial size, both data sets have likely helped de-risk the RSV program, suggesting the asset’s value should rise rather than fall.

That said, they can’t sustain burning $100–150 million per year for another 2–3 years—otherwise, as jbog pointed out, they’ll be in serious trouble.

They allocated $160 million to R&D and $50 million to G&A. If RSV is no longer in the equation (assuming no upfront payments and no further clinical expenses), their costs should drop significantly—potentially to around $60 million for R&D and $30 million for G&A. This would reduce annual cash burn to under $25 million, significantly improving the company’s financial outlook.
👍️ 2
dewophile dewophile 7 horas hace
The peds data was a negative for exactly the reasons we said going into it - enough efficacy to continue the program, but not enough that you have to devise a novel tool to try and tease out the efficacy signal (i.e. nothing concrete like shortened hospital stay). Then the patent was a negative. so if you start at 10 and you tack on two negatives, I guess you end up at 4.9. I think the current share price is totally insane, but you have smart posters like rocky and jbog that think enta is in dire straits (and that perhaps I am insane), so here we are
have a nice weekend
👍️ 7
alertmeipp alertmeipp 8 horas hace
They had two calls for PED and challenge data and then attended the JPM in last few months - still the investment case is just not getting across.

RSV data got treated as negative I think mainly because they can’t seems to get partnership done for anything after myrovet
👍️0
dewophile dewophile 8 horas hace
Lack of transparency is generally a bad thing, and your sentiment seems to be the prevailing one by investors. I already made a pitch for why this may be different so I'll leave it at that
This is continuing a bit of a trend though because they have been more opaque the last two quarters by not holding earnings calls. I think they are fed up w analysts and the stock price which is completely disconnected from the reality of the underlying business if you ask me
👍️ 2
alertmeipp alertmeipp 8 horas hace
I am pretty certain that most of the other shareholders don’t even know about the “issue” we are discussing here.

No one other than us is paying attention to the fact that Enta is now looking to partner out its RSV.

How many know about the $32million tax refund? It is not much, but that alone is 1.5 bucks per share. 35 percent of the market cap ;)

Either we are sitting on a gold mine that is about to be discovered by the market or somehow we are all delusional here.

Not rare for biotech to trade below cash by a bit, especially when their lead program run into trouble.

But here, we are talking about 1/3 and a pipeline that is alive and well.

Odd and the selling continues
👍️ 1
alertmeipp alertmeipp 9 horas hace
Management needs to do something more impactful to change the sentiment on this name

I think RSV partnership, followed by a significant expense will do it.

They will need to raise fund eventually, a depressed stock limit their options,
👍 3
alertmeipp alertmeipp 9 horas hace
Bought some shares - this “delay” likely is a nothing burger but if something is really afoot, I agree that chance is good that it will be positive rather than negative.
👍 1
Jab44 Jab44 10 horas hace
The mere fact shareholders are forced to prognosticate or predict something as simple as a quarterly announcement date is mind boggling. Mr Luly has been in the job for well over 20 years and if he can’t properly communicate to the people who pay his salary what else is he deficient in ?? Leaving shareholders in the dark without a quarterly meeting or some other means of communication when you seem to be floundering is not a recipe for success in my humble opinion.
👍 2
go seek go seek 10 horas hace
Luly: It’s time to explore partnerships in EARNest! JPM call 1/15
👍️ 2
InefficientMarket InefficientMarket 10 horas hace
Beginning with 2016, by this time they had issued a Q1 PR every year without fail. You have to back to 2015 to find Q1 Results issued `without a prior PR.
👍️ 3
dewophile dewophile 11 horas hace
Schwab has earnings as tentative for Monday but they also had earnings for this week earlier in the week so until there is a company PR no one really knows
👍️ 1
Fred Kadiddlehopper Fred Kadiddlehopper 11 horas hace
FWIW my brokerage account has earnings listed for Monday Feb 10th, after market close.
👍️0
biotech_researcher biotech_researcher 12 horas hace
At least this is a low volume dump..
👍️0
InefficientMarket InefficientMarket 12 horas hace
Perhaps they just didn't get the paperwork/accounting done on time this time around.

Put those odds at 1%. I went back through their history of last five years and this is first time they’re this late with a Q1 related PR. Something is afoot. Interesting, yet depressing at same time, that shorts feel comfortable holding under $5.
👍 3
dewophile dewophile 12 horas hace
They have not been late reporting results ever, and as has been pointed out their accounting is super straight forward. I'm waiting to see if they release results today, which is exactly a year to the day from last Q1 earnings. If they don't, then I am a buyer/trader next week assuming change is coming, bc when you have >2x cash in the bank than the MC, change is generally a positive
👍 3
PioneerUniverse8 PioneerUniverse8 12 horas hace
I think it is more of the same, Applying some generalization of Occam's razor principle here, i.e. that the simplest explanation is the most probable. Perhaps they just didn't get the paperwork/accounting done on time this time around.
👍 2
dewophile dewophile 12 horas hace
That is the risk here, but wouldn't you think the weirdness in this earnings cycle means there are changes afoot and not just more of the same?
👍 2
PioneerUniverse8 PioneerUniverse8 13 horas hace
Issues for shareholders emerge when the board prioritizes its own interests over those of the shareholders. I haven't seen this happen in ENTA yet, but there are plenty of example in biotech industry. The risk here is that board/CEO takes it easy with no sense of urgency and looks for partner rather passively, does not entertain the idea of selling the entire company (in pieces or as a whole), progresses with the pipeline and as a consequence burns through cash. So we may be stuck here for a while :)
👍 1
dewophile dewophile 13 horas hace
They are not allowed to tell you when earnings is going to be, or if there is going to be a call along w it before it is public. My experience is that their IR is quite responsive
👍️ 1
dewophile dewophile 13 horas hace
Bruce Carter is chairman of the board. He headed ZGEN through turbulent times and was able to salvage value for investors when BMY bought them out after their clinical drug bombed. I wouldn't be surprised if he pushes to offload all the clinical assets for whatever they can get, probably RSV has value but little else, and he gets the company more focused which frankly should get them to at least close to cash value minus restructuring costs/ finishing spend on RSV. They can probably generate 100M for their royalty interest and have a 30M refund due from the IRS, so doing the math, figuring an additional 50M to wind down RSV program etc., gets us to double digits pretty easily. Assuming they are 80+% enrolled in HR I would even unblind that trial early - it's pretty important to have that data to know the value of the RSV assets
👍️ 5
alertmeipp alertmeipp 14 horas hace
Their IR is pretty useless for retail investors. You can try email or call them. Dont expect to get a response
👍️0
go seek go seek 14 horas hace
Has anyone asked IR about earnings date?
👍️0
alertmeipp alertmeipp 14 horas hace
They just gone thru their year-end process and their business model can’t be more straight forward with zero debt. They don’t even sell their own products and are not getting any other non royalty related income other than interest income. So chance of delay is because of accounting issue seems remote.

If they are indeed going to do a restructure and make the company officially focus on only immunology plus RSV (I assume they will incur cost for staff cut and asset write off etc). I wish they just auction off all the other virology assets include 235 and all related IP. Get whatever they can and move on.

Now looking back, maybe that’s why they removed hpv and 235 partnership from their business goals in latest update.
👍️ 1
dewophile dewophile 15 horas hace
Delaying earnings can be bad too but in this case there is far more potential for a positive catalyst even if there is no deal making. They already intimated they are looking to partner RSV so they can formalize that which means no further clinical development in antivirals after the adult HR study. That would mean a restructuring to a preclinical company effectively which given the cash position should be very good for the stock price.
👍️ 4
alertmeipp alertmeipp 1 día hace
Interesting observation. However, unless they are very close to finalizing the deal, it's hard to see why they would delay the quarterly release and earnings call for it.

They could simply release the earnings first and schedule a separate call once the partnership is officially announced.

I suppose we'll find out in the coming days. Hoping for a nice suprise here.
👍️0
alertmeipp alertmeipp 1 día hace
Re: THRD: Moved up sharply today. Still near all time low. Interesting name but I don’t have enough energy to follow another name in such a distressing sector. Hope it continues to go up and bring more interest towards this kit/stat area
👍️0
DC15 DC15 1 día hace
Relict news: Program of 2023, has since been dropped, presumably.
👍️0
alertmeipp alertmeipp 1 día hace
Imagine the market reaction if they manage to cut a nice RSV deal, will be extraordinary;)
👍️ 3
floblu14 floblu14 1 día hace
Enanta Pharmaceuticals describes new PL-pro inhibitors

BioWorld MedTech February 6, 2025

Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be ...

[Needs subscription.]

https://www.bioworld.com/articles/710689-enanta-pharmaceuticals-describes-new-pl-pro-inhibitors?v=preview
👍️0
alertmeipp alertmeipp 1 día hace
I think there will be lots of no votes if they can’t reverse the trend before March 13.
👍 1
alertmeipp alertmeipp 1 día hace
Lol, talk about negative sentiment here
👍️0
Jab44 Jab44 1 día hace
Two years ago this was $50 now it’s $5. All of the hype regarding EDP-235 has dissipated.And now the focus is fighting a legal battle with a gorilla (Pfizer). Forgive me for questioning this companies strategy. Is 323 worth anything ?? Who knows.
I will be voting no for every current board members nomination.
👍 1
DC15 DC15 2 días hace
Patience, it can take some time to determine the best way to tell everyone that paying Pfizer's attorney fees will bankrupt the company without a significant ATM.
👍 1
vinmantoo vinmantoo 2 días hace
Let me flip your question on its head. Is it conceivable that the delay in announcing the FY1Q25 PR and CC is because there is something of consequence happening right now?

Dew, I was thinking/hoping the same thing.
👍️0
alertmeipp alertmeipp 2 días hace
I am so ready as well. But does seems too early for RSV news as PED data was just released couple months ago..
Wouldn't mind at all, or may even better - a buyout news please.
👍️ 2
dewophile dewophile 2 días hace
Duly noted. Trust me I’m ready for “different” bc more of the same is painful
👍 4 😆 1
go seek go seek 2 días hace
ENANTA PHARMA: Bring on the Good News!
👍️0
DewDiligence DewDiligence 2 días hace
There’s a nuanced difference this time. ENTA’s FY2Q24 and FY3Q24 PRs (on 5/6/24 and 8/5/24, respectively) gave the date of the next quarterly earnings release, but the FY4Q24 PR (on 11/25/24) did not.

Typically, when companies do not hold a quarterly CC and have not previously disclosed the quarterly release date, they issue a “heads-up” PR a week or two before the release date. What’s curious is that ENTA has not (as yet) done this and, further, ENTA is acting differently than it has in the past.

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-39 (FY2Q24)

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-40 (FY3Q24)

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-financial-results-its-fiscal-41 (FY4Q24)
👍 6
dewophile dewophile 2 días hace
I’m not sure there is a delay. In prior quarters w no cc they just released results in a pr w no advance notice. They give a week notice when there is a call scheduled with the PR
Last year q1 results were feb 7. If they don’t release results by end of the week then I’m with you something may be cooking. Right now I’m just assuming results Thursday or Friday with no cc
Doesn’t mean the pr will be devoid of useful info.
It always raises a “what are they hiding that they won’t take questions” type reaction, but they have remained active with investor presentations and always hold a cc when there is important data release like the 323 challenge data and peds 938 data. Let’s face it biotech analysts are not always the smartest and many of the questions in the past have been stupid so I’m not particularly upset about the new format the last couple quarters where they don’t hold earnings ccs but rather just with important data release while hitting the major investors conferences
My 2 cents
👍 4
alertmeipp alertmeipp 2 días hace
I had similar thought couple days ago, but then I saw a notification from my broker that said they will report today so my hope was dashed

I guess now that the Q is not released, what you said is still a possibility
👍️0
DewDiligence DewDiligence 2 días hace
ENTA hasn't yet spent any money on the actual appeal. The expense of filing for an appeal is de minimus and is almost certainly worth whatever it costs from the standpoint of negotiating leverage.
👍️ 4
DewDiligence DewDiligence 2 días hace
Is there really nothing they could talk to the investment community about? Let me flip your question on its head. Is it conceivable that the delay in announcing the FY1Q25 PR and CC is because there is something of consequence happening right now?
👍️ 8 😀 1
alertmeipp alertmeipp 2 días hace
Yeah, I guess not today—no scheduled call, so it’s probably a nonevent anyway.

This is the first time in the past few years that they haven’t held a call for Q1.

Is it really nothing they could talk to the investment community about?
👍️0

Su Consulta Reciente

NASDAQ
ENTA
Enanta Pharmaceuticals
DOWI
DJTEST3
DJTEST3
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios